Apr182018

Lymphoma Patient Survey – Experience with Diffuse Large B Cell Lymphoma (DLBCL)

If you have or had Diffuse Large B Cell Lymphoma (DLBCL), you can help by completing our survey.

Lymphoma Canada is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR). The survey provides us with the patient input required for the submission. pCODR uses this information to help them make recommendations to Canadian public drug plans regarding funding for new cancer drugs.

The funding request under review is: CAR-T cell therapy for relapsed Diffuse Large B Cell Lymphoma (DLBCL)

The survey provides us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

You do not need to live in Canada to complete this survey.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

The survey will be open until midnight Pacific Time on Thursday, May 31, and should only take 10 minutes of your time.

You may access the survey by clicking the appropriate link below.

Survey for DLBCL patients who have experience with CAR-T Cell Therapy

Survey for DLBCL patients who have NOT been treated with CAR-T Cell Therapy

Please share and help us spread the word.

Thank you for your support.

Like with Social Media